Access to anti-retroviral drugs, female in Malta

Malta: Access to anti-retroviral drugs, female was 47.0% in 2024. ▲ Rising

Latest (2024)
47.0%
Change on year
down 35.6%
World rank
124th
of 141 countries
All-time high
74.0%
in 2020
All-time low
20.0%
in 2004
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Malta, 2000–2024

204060802000201220242000: 21 %2001: 24 %2002: 21 %2003: 22 %2004: 20 %2005: 24 %2006: 24 %2007: 26 %2008: 31 %2009: 32 %2010: 32 %2011: 34 %2012: 40 %2013: 43 %2014: 47 %2015: 52 %2016: 54 %2017: 58 %2018: 63 %2019: 68 %2020: 74 %2021: 74 %2022: 74 %2023: 73 %2024: 47 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, female in Malta is 47.0%, measured in 2024.

The figure is down 35.6% on the previous year and unchanged over ten years.

Over the whole period, access to anti-retroviral drugs, female in Malta peaked at 74.0% in 2020 and was at its lowest, 20.0%, in 2004.

Malta ranks 124th of 141 countries on this measure, in the bottom quarter.

The long-run direction has been consistently rising across the 25 years of available data.

Access to anti-retroviral drugs, female in Malta, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Malta, 2000 to 2024.
Year % Change
2000 21.0%
2001 24.0% +14.3%
2002 21.0% -12.5%
2003 22.0% +4.8%
2004 20.0% -9.1%
2005 24.0% +20.0%
2006 24.0% +0.0%
2007 26.0% +8.3%
2008 31.0% +19.2%
2009 32.0% +3.2%
2010 32.0% +0.0%
2011 34.0% +6.2%
2012 40.0% +17.6%
2013 43.0% +7.5%
2014 47.0% +9.3%
2015 52.0% +10.6%
2016 54.0% +3.8%
2017 58.0% +7.4%
2018 63.0% +8.6%
2019 68.0% +7.9%
2020 74.0% +8.8%
2021 74.0% +0.0%
2022 74.0% +0.0%
2023 73.0% -1.4%
2024 47.0% -35.6%

Averages by decade

DecadeAverage LowestHighest Years
2000s 24.5% 20.0% 32.0% 10
2010s 49.1% 32.0% 68.0% 10
2020s 68.4% 47.0% 74.0% 5

Countries ranked near Malta

  1. 122 Angola 50.0% compare
  2. 123 North Macedonia 49.0% compare
  3. 125 Egypt 46.0% compare
  4. 126 Qatar 43.0% compare
  5. 127 Syrian Arab Republic 41.0% compare

See the full ranking of 160 places →

More gender data for Malta

All data for Malta →

Frequently asked questions

What is access to anti-retroviral drugs, female in Malta?
Access to anti-retroviral drugs, female in Malta was 47.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Malta?
The highest recorded value was 74.0% in 2020.
What is the lowest access to anti-retroviral drugs, female recorded in Malta?
The lowest recorded value was 20.0% in 2004.
How does Malta rank for access to anti-retroviral drugs, female?
Malta ranks 124th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Malta?
Over the last ten years it is unchanged. The long-run trend across the full record is rising.
Where does this Malta data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Malta. Statizoid, drawing on UNAIDS estimates. Retrieved 07 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/malta/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/malta/">Access to anti-retroviral drugs, female in Malta</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.